CD8A and neoplasm: BVax therapy demonstrated enhanced CD8+ T cell expansion and durability in GBM, resulting in improved anti-tumor response when juxtaposed with DCs Field (6), a popular therapeutic approach for anti-tumor vaccine development (7, 8).